tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ASND Stock Latest News

ASND Earnings this Week: How Will it Perform?
Pre-EarningsASND Earnings this Week: How Will it Perform?
12h ago
ASND
Ascendis Pharma announces new pooled analysis on TransCon PTH
PremiumThe Fly
Ascendis Pharma announces new pooled analysis on TransCon PTH
3d ago
ASND
Ascendis Pharma Launches Expanded SKYTROFA Dosing in U.S.
PremiumCompany Announcements
Ascendis Pharma Launches Expanded SKYTROFA Dosing in U.S.
19d ago
6K
ASND
RBC Capital remains buyer of Ascendis, says patient death unlikely drug related
PremiumThe Fly
RBC Capital remains buyer of Ascendis, says patient death unlikely drug related
21d ago
ASND
Ascendis Pharma weakness follows death reported in FAERS, says BofA
PremiumThe Fly
Ascendis Pharma weakness follows death reported in FAERS, says BofA
21d ago
ASND
Ascendis Pharma price target raised to $242 from $230 at BofA
PremiumThe FlyAscendis Pharma price target raised to $242 from $230 at BofA
21d ago
ASND
Ascendis Pharma’s Promising Growth: Yorvipath Uptake and Anticipated TransCon CNP Approval Drive Buy Rating
Premium
Ratings
Ascendis Pharma’s Promising Growth: Yorvipath Uptake and Anticipated TransCon CNP Approval Drive Buy Rating
21d ago
ASND
Ascendis Pharma initiated with a Strong Buy at Raymond James
Premium
The Fly
Ascendis Pharma initiated with a Strong Buy at Raymond James
25d ago
ASND
Ascendis Pharma Grants Employee Warrants to Boost Engagement
PremiumCompany Announcements
Ascendis Pharma Grants Employee Warrants to Boost Engagement
26d ago
6K
ASND
Ascendis Pharma price target raised to $254 from $203 at Cantor Fitzgerald
PremiumThe Fly
Ascendis Pharma price target raised to $254 from $203 at Cantor Fitzgerald
28d ago
ASND
Ascendis Pharma Submits EMA Application for Achondroplasia Treatment
PremiumCompany Announcements
Ascendis Pharma Submits EMA Application for Achondroplasia Treatment
1M ago
6K
ASND
Ascendis Pharma submits TransCon CNP marketing authorization application to EMA
PremiumThe Fly
Ascendis Pharma submits TransCon CNP marketing authorization application to EMA
1M ago
ASND
Ascendis Pharma’s Yorvipath: A Competitive Edge in Hypoparathyroidism Treatment Drives Buy Recommendation
PremiumRatingsAscendis Pharma’s Yorvipath: A Competitive Edge in Hypoparathyroidism Treatment Drives Buy Recommendation
1M ago
ASND
Ascendis Pharma Closes Warrant Exercise Window, Boosts Share Capital
Premium
Company Announcements
Ascendis Pharma Closes Warrant Exercise Window, Boosts Share Capital
1M ago
6K
ASND
Wedbush sees no threat to Ascendis’ Yorvipath from competitor data
Premium
The Fly
Wedbush sees no threat to Ascendis’ Yorvipath from competitor data
2M ago
MBX
ASND
Ascendis Pharma’s Market Leadership and Growth Potential in Chronic Hypoparathyroidism
PremiumRatings
Ascendis Pharma’s Market Leadership and Growth Potential in Chronic Hypoparathyroidism
2M ago
ASND
Buy Rating for Ascendis Pharma Driven by Yorvipath’s Efficacy and Upcoming Regulatory Catalysts
PremiumRatings
Buy Rating for Ascendis Pharma Driven by Yorvipath’s Efficacy and Upcoming Regulatory Catalysts
2M ago
ASND
MBX Biosciences price target raised to $80 from $38 at Oppenheimer
PremiumThe Fly
MBX Biosciences price target raised to $80 from $38 at Oppenheimer
2M ago
MBX
ASND
Yun Zhong Reaffirms Buy Rating for Ascendis Pharma Amidst Competitive Uncertainties
PremiumRatings
Yun Zhong Reaffirms Buy Rating for Ascendis Pharma Amidst Competitive Uncertainties
2M ago
ASND
Ascendis Pharma Grants Employee Warrants to Boost Engagement
PremiumCompany AnnouncementsAscendis Pharma Grants Employee Warrants to Boost Engagement
2M ago
6K
ASND
Ascendis Pharma price target raised to $230 from $227 at BofA
Premium
The Fly
Ascendis Pharma price target raised to $230 from $227 at BofA
2M ago
ASND
Ascendis Pharma: Buy Rating Affirmed on Yorvipath Approval and TransCon CNP Prospects
Premium
Ratings
Ascendis Pharma: Buy Rating Affirmed on Yorvipath Approval and TransCon CNP Prospects
2M ago
ASND

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >